Enzymedica, Inc. introduces Reduce™ with Glucoreductase™

Enzymedica, Inc. introduces Reduce™ with Glucoreductase™

Enzymedica, Inc., a manufacturer of indication-specific enzyme-based finished products has introduced Reduce™, a product containing a breakthrough enzyme called Glucoreductase™ blended with natural ingredients chosen for their ability to support healthy blood sugar balance.
David Barton, Enzymedica’s Director of Education explains, “The carbohydrate-rich Western diet has contributed to over 57 million people in the United States with a pre-diabetic condition. If healthy lifestyle strategies are not undertaken, many of these individuals are on a path to hyperinsulin response, insulin resistance, and later a diagnosis of diabetes.”

A dietary supplement effective in reducing the levels of sugar found in the blood following a carbohydrate rich meal offers important health potential. When we eat carbohydrates the body breaks the starch into simple sugars using natural digestive enzymes. Glucoreductase™ works by combining these simple sugars to form a soluble fiber. The fiber serves as a food source for the beneficial microflora in the intestinal tract and will not contribute to the rise of glucose. This breakthrough dramatically reduces the conversion of carbohydrates to glucose and lessens the demand for insulin production.

Reduce combines Glucoreductase™, along with cinnamon extract, chromium picolinate, and zinc gluconate; nutrients shown to provide significant benefit for healthy blood sugar regulation. The enzymes in Reduce work by forming the soluble fiber, and the additional ingredients support the body by tranporting sugar from the blood into the body’s cells, safely reducing serum glucose levels. This process makes insulin work more efficiently and helps combat insulin resistance. Additionally, the reduction of blood glucose leaves less sugar for the liver to convert into triglycerides or to later be stored as fat.

James Blum, Ph. D., of the Dietary Supplement Research Group in Portand, Maine conducted a clinical trial to assess the efficacy of Reduce. Reduce was studied for its effectiveness at promoting healthy fasting blood glucose levels, lower blood glucose levels after a meal, and healthier quality of life with increased energy. The experiment tested subjects’ serum blood glucose before and after a standard starch meal, both with and without the addition of Reduce. The study demonstrated that Reduce lowered what would have been the amount of sugar found in the subject’s blood following the meal by as much as 40%, depending on the quantity of the product [Reduce] that was taken.

The clinical trial is in the process of peer-review publication.

Enzymedica CEO Tom Bohager adds, “With millions of Americans facing the prospect of inflammatory metabolic syndrome, adult onset diabetes, and pancreatic insufficiency, we are extremely proud to offer Reduce, a blood sugar support formula backed by recognized study results.”

Enzymedica offers Reduce in both 30 and 90 capsule size bottles.

To learn more about Enzymedica’s Reduce as well as purchase locations, visit www.enzymedica.com.

About Enzymedica, Inc.:
Florida-based Enzymedica, Inc., was founded in 1998 to offer consumers targeted enzyme products that address digestion issues, food allergies and intolerances, cardiovascular issues, immune function and inflammation. The exclusive Enzymedica Thera-blend™ process combines different strains of each major enzyme to work more broadly in the digestive tract and throughout the entire body. Enzymedica's products are made from only the highest quality plant and plant-based enzymes and are 100 percent vegan and vegetarian.

Hide comments


  • Allowed HTML tags: <em> <strong> <blockquote> <br> <p>

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.